Complete Response Letters In Lieu Of Inspections: What To Expect During COVID-19
Executive Summary
If agency has concerns about facilities it cannot inspect, it will generally issue complete responses, Q&A guidance says.
You may also be interested in...
Internal FDA Guidance Further Constrains GDUFA III Get-Out-Of-OAI Card
Generic drug firms won a narrow commitment from the US FDA to approve ANDAs without revisiting sites previously deemed deficient. But the agency's just-issued MAPP document implementing the commitment, which stems from pandemic-era travel frustrations, is narrower still. Recent reinspection results might explain why.
Internal FDA Guidance Further Constrains GDUFA III Get-Out-Of-OAI Card
Generic drug firms won a narrow commitment from the US FDA to approve ANDAs without revisiting sites previously deemed deficient. But the agency's just-issued MAPP document implementing the commitment, which stems from pandemic-era travel frustrations, is narrower still. Recent reinspection results might explain why.
Novartis Counts On Adherence, Access And Affordability To Ensure Inclisiran’s US Success
The company has said coverage under medical benefit could mean $0 copays for many patients, potentially overcoming a hurdle to uptake in the biologic cholesterol market.